Faron Pharmaceuticals Oy

Company Profile

• Business description

  Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.

• Contact

  Joukahaisenkatu 6 B
  Turku20520
  FIN

  T: +358 24695151

  E: [email protected]

  https://www.faron.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  33